Danaher (NYSE:DHR) Given New $290.00 Price Target at Citigroup

Danaher (NYSE:DHR) had its target price lifted by Citigroup from $280.00 to $290.00 in a research note released on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the conglomerate’s stock.

A number of other equities analysts have also recently weighed in on DHR. StockNews.com cut shares of Danaher from a buy rating to a hold rating in a research report on Wednesday, January 31st. HSBC upgraded shares of Danaher from a hold rating to a buy rating and upped their target price for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Barclays upped their target price on shares of Danaher from $260.00 to $270.00 and gave the company an equal weight rating in a research note on Wednesday. Raymond James upped their target price on shares of Danaher from $240.00 to $270.00 and gave the company an outperform rating in a research note on Wednesday, January 31st. Finally, TD Cowen upped their target price on shares of Danaher from $280.00 to $290.00 and gave the company a buy rating in a research note on Wednesday. Six investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average target price of $270.00.

Danaher Stock Down 1.1 %

Shares of Danaher stock opened at $250.41 on Wednesday. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. The company has a fifty day moving average price of $249.00 and a 200 day moving average price of $230.78. The stock has a market cap of $185.44 billion, a price-to-earnings ratio of 39.19, a price-to-earnings-growth ratio of 3.96 and a beta of 0.83. Danaher has a twelve month low of $182.09 and a twelve month high of $259.00.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The firm’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.36 EPS. Equities research analysts forecast that Danaher will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be given a $0.27 dividend. This is a boost from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 annualized dividend and a yield of 0.43%. Danaher’s dividend payout ratio is 16.90%.

Insiders Place Their Bets

In other news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,957 shares of company stock worth $8,265,802. Insiders own 10.90% of the company’s stock.

Institutional Trading of Danaher

A number of large investors have recently added to or reduced their stakes in DHR. Cape Investment Advisory Inc. bought a new stake in Danaher during the fourth quarter worth approximately $25,000. Tsfg LLC boosted its holdings in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares in the last quarter. BKM Wealth Management LLC bought a new stake in Danaher during the fourth quarter worth approximately $27,000. Wetzel Investment Advisors Inc. bought a new stake in Danaher during the fourth quarter worth approximately $29,000. Finally, OFI Invest Asset Management purchased a new stake in shares of Danaher in the 3rd quarter valued at approximately $30,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.